A man who wanted to commit suicide by hanging himself: An adverse effect of ciprofloxacin

General Hospital Psychiatry

Volumn 33, Issue 1, 2011, Pages 82.e5-82.e7

  Ahmed, Amir I A ^a,b   van der Heijden, Frank M M A ^a   van den Berkmortel, Hanneke ^a   Kramers, Kees ^b  

^a GGZ Noord en Midden Limburg ^*  (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Central nervous system; Ciprofloxacin; Depression; Fluoroquinolone; Neuropsychiatric adverse effects; Suicidal ideations

Indexed keywords

AMLODIPINE; ANTIDEPRESSANT AGENT; CIPROFLOXACIN; PERINDOPRIL;

ABNORMAL BEHAVIOR; ADULT; ANAMNESIS; ANHEDONIA; ANOREXIA; ARTICLE; CASE REPORT; CRYING; DEPRESSION; DISEASE DURATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FATIGUE; GASTROINTESTINAL TOXICITY; GUILT; HANGING; HUMAN; HYPERTENSION; INSOMNIA; MALE; PROSTATITIS; RECURRENT DISEASE; SUICIDAL IDEATION; SUICIDE ATTEMPT;

EID: 79951855850     PISSN: 01638343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.genhosppsych.2010.07.002     Document Type: Article

References (22)

1. Naranjo C.A., Busto U., Sellers E.M., et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981, 30(2):239-245.
2. Owens R.C., Ambrose P.G. Clinical use of the fluoroquinolones. Med Clin North Am 2000, 84(6):1447-1469.
3. Owens R.C., Ambrose P.G. Antimicrobial safety: focus on fluoroquinolones. Clin Infect Dis 2005, 41(Suppl 2):S144-S157.
4. Schacht P., Arcieri G., Hullmann R. Safety of oral ciprofloxacin: an update based on clinical trial results. Am J Med 1989, 87(5A):98S-102S.
5. Steinert T., Studemund H. Acute delusional parasitosis under treatment with ciprofloxacin. Pharmacopsychiatry 2006, 39(4):159-160.
6. Agbaht K., Bitik B., Piskinpasa S., et al. Ciprofloxacin-associated seizures in a patient with underlying thyrotoxicosis: case report and literature review. Int J Clin Pharmacol Ther 2009, 47(5):303-310.
7. Christ W. Central nervous system toxicity of quinolones: human and animal findings. J Antimicrob Chemother 1990, 26(Suppl B):219-225.
8. LaSalvia E.A., Domek G.J., Gitlin D.F. Fluoroquinolone-induced suicidal ideation. Gen Hosp Psychiatry 2010, 32(1):108-110.
9. Olivier P., Bertrand L., Tubery M., et al. Hospitalizations because of adverse drug reactions in elderly patients admitted through the emergency department: a prospective survey. Drugs Aging 2009, 26(6):475-482.
10. Bednarczyk E.M., Adler L.P., Remler B., et al. Assessment of the effects of ciprofloxacin and nalidixic acid on cerebral blood flow and metabolism in healthy subjects by positron emission tomography. Pharmacotherapy 1994, 14:153-161.
11. Unseld E., Zeilger G., Gemeinhardt A., et al. Possible interaction of fluoroquinolones with the benzodiazepine-GABA A-receptor complex. Br J Clin Pharmacol 1990, 30:63-70.
12. Peeters B.W., Vanderheyden P.M. In vitro and in vivo characterization of the NMDA receptor-linked strychnine-insensitive glycine site. Epilepsy Res 1992, 12(2):157-162.
13. Stahlmann R. Clinical toxicological aspects of fluoroquinolones. Toxicol Lett 2002, 127(1-3):269-277.
14. Radandt J.M., Marchbanks C.R., Dudley M.N. Interactions of fluoroquinolones with other drugs: mechanisms, variability, clinical significance, and management. Clin Infectious Diseases 1992, 14:272-284.
15. Robertson H.T., Allison D.B. Drugs associated with more suicidal ideations are also associated with more suicide attempts. PLoS One 2009, 4(10):e7312.
16. McLellan R.A., Drobitch R.K., Monshouwer M., et al. Fluoroquinolone antibiotics inhibit cytochrome P450-mediated microsomal drug metabolism in rat and human. Drug Metab Dispos 1996, 24:1134-1138.
17. Herrlin K., Segerdahl M., Gustafsson L.L., et al. Methadone, ciprofloxacin, and adverse drug reactions. Lancet 2000, 356:2069-2070.
18. Zanchetti A., Omboni S., La Commare P., et al. Efficacy, tolerability, and impact on quality of life of long-term treatment with manidipine or amlodipine in patients with essential hypertension. J Cardiovasc Pharmacol 2001, 38(4):642-650.
19. de la Rosette J.J., Ruijgrok M.C., Jeuken J.M., et al. Personality variables involved in chronic prostatitis. Urology 1993, 42:654-662.
20. Berghuis J.P., Heiman J.R., Rothman I., et al. Psychological and physical factors involved in chronic idiopathic prostatitis. J Psychosom Res 1996, 41:313-325.
21. Egan K.J., Krieger J.N. Psychological problems in chronic prostatitis patients with pain. Clin J Pain 1994, 10:218-226.
22. Reddy D.S., Jian K. The testosterone-derived neurosteroid androstanediol is a positive allosteric modulator of GABA-A receptors. J Pharmacol Exp Ther 2010.